Carbachol
A cholinomimetic agent that stimulates both muscarinic and nicotinic receptors, used as eye drops to treat glaucoma by lowering intraocular pressure and as an intraocular agent during eye surgery to produce rapid pupil constriction. It is resistant to breakdown by cholinesterases, giving it a longer duration of action than acetylcholine. Systemic absorption can cause significant parasympathetic side effects.
Masse moléculaire
182,6500 g/mol
TPSA
52,30 Ų
Mécanisme d'action
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Structure 2D
Cite this structure
Embed this structure
SMILES
C[N+](C)(C)CCOC(N)=O.[Cl-]
InChI
InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H
Molecular Formula
C6H15ClN2O2
HBD / HBA
1 / 3
Liaisons Rotatives
4
Atomes Lourds
11
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A cholinomimetic agent that stimulates both muscarinic and nicotinic receptors, used as eye drops to treat glaucoma by lowering intraocular pressure and as an intraocular agent during eye surgery to produce rapid pupil constriction. It is resistant to breakdown by cholinesterases, giving it a longer duration of action than acetylcholine. Systemic absorption can cause significant parasympathetic side effects.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Carbachol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL14. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5831. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="carbachol"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/carbachol/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/carbachol/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/carbachol/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="carbachol"></drugfyi-drug>